NDAORALTABLETPriority Review
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Clinical Trials (5)
A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.
Started Jul 2024
29 enrolled
Lung Cancer
Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
Started Jun 2021
307 enrolled
Lung Cancer
Korea Post Marketing Surveillance (PMS) Study of Vizimpro
Started Mar 2021
188 enrolled
Lung Neoplasms
Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
Started Aug 2020
101 enrolled
Metastatic Non Small Cell Lung Cancer
Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)
Started Jan 2020
40 enrolled
EGFR Mutation-positive Inoperable or Reccrent NSCLC
Loss of Exclusivity
LOE Date
Sep 27, 2032
79 months away
Patent Expiry
Sep 27, 2032